Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Inmune Bio (INMB) over the last 6 years, with Q3 2025 value amounting to $961000.0.

  • Inmune Bio's Non Operating Income rose 39792.75% to $961000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 44145.45%. This contributed to the annual value of $553000.0 for FY2024, which is 30711.61% up from last year.
  • According to the latest figures from Q3 2025, Inmune Bio's Non Operating Income is $961000.0, which was up 39792.75% from $113000.0 recorded in Q2 2025.
  • Over the past 5 years, Inmune Bio's Non Operating Income peaked at $961000.0 during Q3 2025, and registered a low of -$2.5 million during Q4 2022.
  • Its 5-year average for Non Operating Income is $92368.4, with a median of $119000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Inmune Bio's Non Operating Income was 541250.0% (2022), while the steepest drop was 49079.56% (2022).
  • Quarter analysis of 5 years shows Inmune Bio's Non Operating Income stood at $641000.0 in 2021, then crashed by 490.8% to -$2.5 million in 2022, then soared by 98.84% to -$29000.0 in 2023, then surged by 958.62% to $249000.0 in 2024, then surged by 285.94% to $961000.0 in 2025.
  • Its Non Operating Income stands at $961000.0 for Q3 2025, versus $113000.0 for Q2 2025 and $166000.0 for Q1 2025.